EFNS guidelines on pharmacological treatment of neuropathic pain

@article{Attal2006EFNSGO,
  title={EFNS guidelines on pharmacological treatment of neuropathic pain},
  author={Nadine Attal and Giorgio Cruccu and Maija L Haanp{\"a}{\"a} and Per T. Hansson and Troels Staehelin Jensen and Turo Nurmikko and Cristina Sampaio and S{\o}ren Hein Sindrup and Philip J Wiffen},
  journal={European Journal of Neurology},
  year={2006},
  volume={13}
}
Neuropathic pain treatment remains unsatisfactory despite a substantial increase in the number of trials. [] Key Method Studies were identified using first the Cochrane Database then Medline. Trials were classified according to the aetiological condition. All class I and II controlled trials (according to EFNS classification of evidence) were assessed, but lower-class studies were considered in conditions that had no top level studies. Only treatments feasible in an outpatient setting were evaluated. Effects…

Algorithm for neuropathic pain treatment: An evidence based proposal

NNT and NNH are currently the best way to assess relative efficacy and safety, but the need for dichotomous data, which may have to be estimated retrospectively for old trials, and the methodological complexity of pooling data from small cross-over and large parallel group trials, remain as limitations.

Treatment of neuropathic pain: an overview of recent guidelines.

Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.

The objectives of the current article are to review the Neuropathic Pain Special Interest Group guidelines for the pharmacological management of neuropathic pain and to provide a brief overview of several recent clinical trials.

Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society.

Randomized, controlled trials, systematic reviews and existing guidelines focusing on the pharmacological management of NeP were evaluated at a consensus meeting and recommendations for treatment are based on degree of evidence of analgesic efficacy, safety, ease of use and cost-effectiveness.

Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms?

Improving the current way of conducting clinical trials in NP could contribute to reduce therapeutic failures and may have an impact on future therapeutic algorithms.

Toward a definition of pharmacoresistant neuropathic pain

The Pharmacological Therapy of Chronic Neuropathic Pain.

Current treatment recommendations on the basis of a selective review of the literature are presented, concluded that tricyclic antidepressants, selective serotonin- norepinephrine reuptake inhibitors, and calcium-channel anticonvulsants are the drugs of first choice for neuropathic pain.

Review and recommendations Pharmacologic management of neuropathic pain: Evidence-based recommendations

Systematic literature reviews, randomized clinical trials, and existing guidelines were evaluated at a consensus meeting and recommended first-line treatments include certain antidepressants, gabapentin and pregabalin, and topical lidocaine.

Management of neuropathic pain

For each patient, considerations on the underlying pain mechanisms, immediate and potential long-term side effects, and price as well as comorbidities and concurrent medications will decide which drug should be the first choice, but until further progress is made towards a mechanism-based classification, treatment is likely to be a trial-and-error process where drug combinations may also be considered.
...

References

SHOWING 1-10 OF 163 REFERENCES

Algorithm for neuropathic pain treatment: An evidence based proposal

NNT and NNH are currently the best way to assess relative efficacy and safety, but the need for dichotomous data, which may have to be estimated retrospectively for old trials, and the methodological complexity of pooling data from small cross-over and large parallel group trials, remain as limitations.

Chronic Neuropathic Pain: Mechanisms and Treatment

  • N. Attal
  • Psychology
    The Clinical journal of pain
  • 2000
A mechanism‐based approach seems promising for clinical research studies, although its application in current management remains challenging.

Lack of efficacy of riluzole in the treatment of peripheral neuropathic pain conditions

Doses of riluzole at (100 mg or above) those used for the treatment of ALS were not effective in alleviating peripheral neuropathic pain.

Antidepressants for neuropathic pain.

This update has provided additional confirmation on the effectiveness of antidepressants for neuropathic pain and has provided new information on another antidepressant - venlafaxine.

Carbamazepine for acute and chronic pain.

To evaluate the analgesic effectiveness and adverse effects of the anticonvulsant medicine carbamazepine for pain management in clinical practice and to identify a clinical research agenda, randomised trials of anticonVulsants in acute, chronic or cancer pain were evaluated.

Oral opioid therapy for chronic peripheral and central neuropathic pain.

The reduction in the intensity of neuropathic pain was significantly greater during treatment with higher doses of opioids than with lower doses, and higher doses produced more side effects without significant additional benefit in terms of other outcome measures.

Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic Review

The evidence base supports the oral use of tricyclic antidepressants, certain opioids, and gabapentinoids in PHN, and a single study of spinal intrathecal administration of lidocaine and methylprednisolone demonstrated efficacy, although this has yet to be replicated.

The use of oral mexiletine for the treatment of pain after peripheral nerve injury.

Mexiletine may be effective in reducing neuropathic pain for patients in whom alternative pain medications have been unsatisfactory, and is found to produce a statistically significant reduction in reported pain when compared to baseline or placebo.
...